Pharmaceutical cocrystals are composed of a drug and a coformer and are currently gaining attention due to their possibility of improving drug solubility. Quantitative determination of cocrystals is usually carried out by liquid chromatography method, but an alternative for the same is derivative UV spectrophotometry. Cocrystals of lamotrigine (LAM) were formed with nicotinamide (NIC) in order to improve the solubility of LAM. The aim of this study was to develop and validate a simple, low-cost, environment friendly, first-order derivative spectrophotometric method for simultaneous determination of LAM and NIC in cocrystals. Determination of LAM and NIC was performed at 244.4 and 271.6 nm, respectively. The method was accurate with recovery values of 98.21-101.52%, and precise (relative standard deviation (RSD) < 1.88%). Robustness evaluated by Plackett-Burman design showed no significant influence of the factors (pH, scanning speed, and sonication time) on LAM and NIC assays. The developed method was compared with a high performance liquid chromatography (HPLC) method and applied to study the cocrystal stoichiometry and solubility. The results indicated a molar ratio of 1:1 and that the cocrystal is more soluble than the drug. This study demonstrated that the first-order derivative method is feasible for drug and coformer determination in cocrystals and is a suitable alternative to chromatographic methods.

A method using liquid chromatography has been developed and validated for determination of buclizine in pharmaceutical formulations and in release studies. Isocratic chromatography was performed on a C18 column with methanol:water (80:20 v/v, pH 2.6) as mobile phase, at a flow rate of 1.0 mL/min, and UV detection at 230 nm. The method was linear, accurate, precise, sensible and robust. The dissolution test was optimized and validated in terms of dissolution medium, apparatus agitation and rotation speed. The presented analytical and dissolution procedures can be conveniently adopted in the quality and stability control of buclizine in tablets and oral suspension.